193 related articles for article (PubMed ID: 37444542)
1. Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.
Khazan N; Quarato ER; Singh NA; Snyder CWA; Moore T; Miller JP; Yasui M; Teramoto Y; Goto T; Reshi S; Hong J; Zhang N; Pandey D; Srivastava P; Morell A; Kawano H; Kawano Y; Conley T; Sahasrabudhe DM; Yano N; Miyamoto H; Aljitawi O; Liesveld J; Becker MW; Calvi LM; Zhovmer AS; Tabdanov ED; Dokholyan NV; Linehan DC; Hansen JN; Gerber SA; Sharon A; Khera MK; Jurutka PW; Rochel N; Kim KK; Rowswell-Turner RB; Singh RK; Moore RG
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444542
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
Khazan N; Kim KK; Hansen JN; Singh NA; Moore T; Snyder CWA; Pandita R; Strawderman M; Fujihara M; Takamura Y; Jian Y; Battaglia N; Yano N; Teramoto Y; Arnold LA; Hopson R; Kishor K; Nayak S; Ojha D; Sharon A; Ashton JM; Wang J; Milano MT; Miyamoto H; Linehan DC; Gerber SA; Kawar N; Singh AP; Tabdanov ED; Dokholyan NV; Kakuta H; Jurutka PW; Schor NF; Rowswell-Turner RB; Singh RK; Moore RG
J Med Chem; 2022 Apr; 65(8):6039-6055. PubMed ID: 35404047
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
Moravej A; Karimi MH; Geramizadeh B; Azarpira N; Zarnani AH; Yaghobi R; Khosravi M; Kalani M; Gharesi-Fard B
Immunol Invest; 2017 Jan; 46(1):80-96. PubMed ID: 27736253
[TBL] [Abstract][Full Text] [Related]
4. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
5. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.
Yang X; Ma L; Zhang X; Huang L; Wei J
Exp Hematol Oncol; 2022 Mar; 11(1):11. PubMed ID: 35236415
[TBL] [Abstract][Full Text] [Related]
6. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
[TBL] [Abstract][Full Text] [Related]
8. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
9. High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms.
Sampaio LR; Viana MA; de Oliveira VS; Ferreira BV; Melo MML; de Oliveira RTG; Borges DP; Magalhãesa SMM; Pinheiro RF
Hematol Transfus Cell Ther; 2024; 46(2):146-152. PubMed ID: 37543491
[TBL] [Abstract][Full Text] [Related]
10. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
16. The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.
Jimbu L; Mesaros O; Neaga A; Nanut AM; Tomuleasa C; Dima D; Bocsan C; Zdrenghea M
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832887
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol potentiates vitamin D and nuclear receptor signaling.
Dampf Stone A; Batie SF; Sabir MS; Jacobs ET; Lee JH; Whitfield GK; Haussler MR; Jurutka PW
J Cell Biochem; 2015 Jun; 116(6):1130-43. PubMed ID: 25536521
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
20. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
